Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug –drug interactions with oral targeted therapy

ConclusionThis is the first prospective study evaluating the relevance of proactive BPMH by pharmacist with contact to the community pharmacy during the inclusion step of a clinical trial to ensure the efficacy and safety of the investigated drug. This investigation was thus able to highlight the statistically significant impact of these DDI on palbociclib plasma concentration variation during the clinical trial.Trial registrationClinicaltrials.gov identifier NCT04025541.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research